Sage Therapeutics announced it will host the first Sage Science Spotlight webcast focused on an in-depth review of SAGE-718. Sage will provide details on its progress with SAGE-718, the company’s lead neuropsychiatry product candidate being explored for the potential treatment of cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. Sage will also share additional details on the recently announced data from the PARADIGM Study of SAGE-718 in patients with mild cognitive impairment due to Parkinson’s disease and the planned initiation of a Phase 2 placebo-controlled study in Huntington’s disease. Additionally, the Company will discuss the unmet need in Huntington’s disease, with participation and perspectives from a leading neurologist and a patient advocate. The Sage Science Spotlight is a new webcast series designed to take a deeper look at Sage’s work in brain health. It will complement Sage’s annual FutureCast event, which provides an update on the company’s overall research and development strategy and clinical progress in its key depression, neurology and neuropsychiatry franchise programs.